Page 3 - Human Use News Today

Artillery fire on both sides was constant this. Entire villages were wiped off the map and. Never before had so many soldiers been killed in such a limited area. Or Dead Mans Hill was the scene of particularly bitter fighting. At the end of the Battle One Of The Hills Two summits was ten meters lower than it was before. Served as a laboratory for testing new weapons the german army fired poison gas in shells here for the first time. This allowed for more accurate targeting. The effect on french ...

Hello on a very warm welcome to news from the world of arts and culture coming up in the next quarter of an hour. Germany and its former colonies are cooperating on the return of looted up from colonial times. Talk of Climate Change is on all our lives and the Frankfurt Book Fair Climate Fiction is booming. And well be strutting down the paris catwalks to see all the latest oarsmen winter fashion trends. In recent years theres been a lot of talk about former colonial powers returning cultural ja...

In the past few weeks, the European Commission provided marketing authorization for biosimilars of denosumab and omalizumab, as well as an ophthalmic formulation of bevacizumab.

AbbVie (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Skyrizi (risankizumab) in the EU to treat adults with moderately to severely active ulcerative colitis (UC).

SUZHOU, China, June 2, 2024 /PRNewswire/ — CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and…

EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and overall survival (OS) benefits of sugemalimab

EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and...

GNW-Adhoc: Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 () | aktiencheck.de

Allschwil, Switzerland - May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia's endothelin receptor antagonist, will be presented by Prof.

31.05.2024 - Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, ...